Clinical Trials Logo

RSV Infection clinical trials

View clinical trials related to RSV Infection.

Filter by:

NCT ID: NCT05550545 Recruiting - Quality of Life Clinical Trials

Infant RSV Infections and Health-related Quality of Life of Families

ResQFamily
Start date: September 29, 2022
Phase:
Study type: Observational

Until today, there is only little information available on how severe RSV infection leading to hospitalisation of the infant impacts the quality of life of affected families. For the ResQ Family project, an online questionnaire will be used to survey parents or caregivers of children up to 24 months currently or recently hospitalised (length of hospital stay of at least 12 hours and hospital admission no longer than 4 weeks ago) due to RSV infection. The aim of the ResQ Family project is to find out how infant RSV hospitalisation impacts the quality of life of affected children and their families. The goal is further to provide scientific evidence on the burden of RSV and raise awareness among all relevant stakeholders including healthcare professionals and patient representatives, decision-makers and the general public. The project will run until June 2024. Data collection will take place during the RSV season from fall 2022 to spring 2023 in four European countries: France, Germany, Italy, and Sweden.

NCT ID: NCT04743609 Recruiting - Pneumonia Clinical Trials

RSV Burden in Outpatient Settings

Oursyn
Start date: February 8, 2021
Phase:
Study type: Observational

Strengthening outpatient low respiratory tract infection surveillance to document the burden of Respiratory Syncytial Virus (RSV)

NCT ID: NCT03728413 Recruiting - RSV Infection Clinical Trials

The Impact of Age on Adaptive Immunity in Adults Infected With Respiratory Syncytial Virus

INFLAMMAGE
Start date: March 5, 2019
Phase: N/A
Study type: Interventional

This study will for the first time systematically investigate the immune responses in an elderly cohort challenged with a well-defined RSV inoculum. With a global aging population and continuing difficulties in generating vaccines that can reliably induce protective immunity in the elderly, these data will indicate the targets at which development of vaccines against RSV and other infections should be directed.

NCT ID: NCT03596801 Recruiting - RSV Infection Clinical Trials

Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children

Start date: June 25, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the infectivity, safety, and immunogenicity of a single dose of recombinant, live-attenuated respiratory syncytial virus (RSV) vaccines (RSV 6120/∆NS1 or RSV 6120/F1/G2/∆NS1) in RSV-seropositive children 12 to 59 months of age and RSV-seronegative infants and children 6 to 24 months of age.